Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Heart Transplant
Phase of Trial: Phase IV
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Proof of concept; Therapeutic Use
- 27 Dec 2017 Status changed from not yet recruiting to recruiting.
- 04 Oct 2017 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.
- 04 Oct 2017 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2021.